Sanjay Shah1, Vijay Khajuria2, Vishal R Tandon3, Zahid H Gillani4, Mohan Lal5. 1. Senior Demonstrator, Department of Pharmacology, Government Medical College , Jammu and Kashmir, India . 2. Associate Professor, Department of Pharmacology, Government Medical College , Jammu and Kashmir, India . 3. Assistant Professor, Department of Pharmacology, Government Medical College , Jammu and Kashmir, India . 4. Professor and Head, Department of Pharmacology, Government Medical College , Jammu and Kashmir, India . 5. Ex-Professor & Head, Department of Cardiology, Government Medical College , Jammu and Kashmir, India .
Abstract
AIM: To compare the safety and efficacy of Enoxaparin (EX) and Fondaparinux (FD) in patients with Unstable Coronary Artery Disease (UCAD). MATERIALS AND METHODS: A prospective, open label, randomized comparative study was designed to study the comparative efficacy and safety of EX and FD in UCAD patients. Recovery, recurrence, major and minor bleeding and biochemical investigations were evaluated and compared among two arms. RESULTS: The baseline demographic characteristics were similar in both groups, with mean age of 56.05 and 56.05 years in EX and FD group respectively. Recovery was equal in two arms. Recurrent MI or angina was seen numerically more in EX group, but it did not statistically vary from that in the FD group. Incidence of haemorrhage was similar in both groups at 9 days, but at 30 days, EX showed a higher incidence (p<0.05). Deaths were prevented in both the treatment arms. Bleeding parameters such as BT, CT and platelet count were not altered in both groups. CONCLUSION:FD appeared to be better than EX in efficacy, as was indicated by a numerically more decrease in recurrence of angina or MI. FD regimen group also had better safety profile, as there was no incidence of haemorrhage at 30 days Therefore, we conclude that FD is an attractive option than EX in UCAD patients.
RCT Entities:
AIM: To compare the safety and efficacy of Enoxaparin (EX) and Fondaparinux (FD) in patients with Unstable Coronary Artery Disease (UCAD). MATERIALS AND METHODS: A prospective, open label, randomized comparative study was designed to study the comparative efficacy and safety of EX and FD in UCAD patients. Recovery, recurrence, major and minor bleeding and biochemical investigations were evaluated and compared among two arms. RESULTS: The baseline demographic characteristics were similar in both groups, with mean age of 56.05 and 56.05 years in EX and FD group respectively. Recovery was equal in two arms. Recurrent MI or angina was seen numerically more in EX group, but it did not statistically vary from that in the FD group. Incidence of haemorrhage was similar in both groups at 9 days, but at 30 days, EX showed a higher incidence (p<0.05). Deaths were prevented in both the treatment arms. Bleeding parameters such as BT, CT and platelet count were not altered in both groups. CONCLUSION: FD appeared to be better than EX in efficacy, as was indicated by a numerically more decrease in recurrence of angina or MI. FD regimen group also had better safety profile, as there was no incidence of haemorrhage at 30 days Therefore, we conclude that FD is an attractive option than EX in UCAD patients.
Authors: Jean-Pierre Bassand; Christian W Hamm; Diego Ardissino; Eric Boersma; Andrzej Budaj; Francisco Fernández-Avilés; Keith A A Fox; David Hasdai; E Magnus Ohman; Lars Wallentin; William Wijns Journal: Eur Heart J Date: 2007-06-14 Impact factor: 29.983
Authors: Jeffrey L Anderson; Cynthia D Adams; Elliott M Antman; Charles R Bridges; Robert M Califf; Donald E Casey; William E Chavey; Francis M Fesmire; Judith S Hochman; Thomas N Levin; A Michael Lincoff; Eric D Peterson; Pierre Theroux; Nanette Kass Wenger; R Scott Wright; Sidney C Smith Journal: Circulation Date: 2011-03-28 Impact factor: 29.690
Authors: Shamir R Mehta; Philippe Gabriel Steg; Christopher B Granger; Jean-Pierre Bassand; David P Faxon; Jeffrey I Weitz; Rizwan Afzal; Bonnie Rush; Ron J G Peters; Madhu K Natarajan; James L Velianou; David M Goodhart; Marino Labinaz; Jean-Francois Tanguay; Keith A A Fox; Salim Yusuf Journal: Circulation Date: 2005-03-22 Impact factor: 29.690
Authors: Erik Diderholm; Bertil Andrén; Gunnar Frostfeldt; Margareta Genberg; Tomas Jernberg; Bo Lagerqvist; Bertil Lindahl; Per Venge; Lars Wallentin Journal: Am Heart J Date: 2002-05 Impact factor: 4.749
Authors: Salim Yusuf; Shamir R Mehta; Susan Chrolavicius; Rizwan Afzal; Janice Pogue; Christopher B Granger; Andrzej Budaj; Ron J G Peters; Jean-Pierre Bassand; Lars Wallentin; Campbell Joyner; Keith A A Fox Journal: N Engl J Med Date: 2006-03-14 Impact factor: 91.245
Authors: Melvin Lafeber; Wilko Spiering; Yolanda van der Graaf; Hendrik Nathoe; Michiel L Bots; Diederick E Grobbee; Frank L J Visseren Journal: Am Heart J Date: 2013-06-15 Impact factor: 4.749